Search Results - hepatocellular+carcinoma

8 Results Sort By:
High-Affinity Mouse Monoclonal Antibodies to GPC-3 for Liver Cancer Research
Abstract: The National Cancer Institute Laboratory of Molecular Biology seeks parties for collaborative research to co-develop and commercialize antibody drug/toxin conjugates as liver cancer therapy and diagnostics.  There is great interest and value in developing more sensitive and efficient agents for earlier detection of hepatocellular cancer (HCC). ...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Yen Phung, Wei Gao, Yifan Zhang
Keywords(s): ANTIBODY, GLYCOPROTEIN, Glypican-3, GPC3, HCC, hepatocellular carcinoma, liver, monoclonal
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing
A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma
Abstract: Early detection of liver cancer, such as hepatocellular carcinoma (HCC), is key to improve cancer-related mortality. More than 800,000 people are diagnosed with this cancer each year throughout the world. Liver cancer is also a leading cause of cancer deaths worldwide, accounting for more than 700,000 deaths each year. Currently, millions...
Published: 4/8/2024   |   Inventor(s): Xin Wei Wang, Jinping Liu, Wei Tang
Keywords(s): Biomarker, HCC, hepatocellular carcinoma, Liver cancer, viral infection, Wang
Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Diagnostics
Single-domain monoclonal antibodies for the treatment of hepatocellular carcinoma
Abstract: The National Cancer Institute seeks parties to license human monoclonal antibodies and immunoconjugates and co-develop, evaluate, and/or commercialize large-scale antibody production and hepatocellular carcinoma (HCC) xenograft mouse models. An advantage of these monoclonal antibodies as a potential therapeutic is their specificity, which...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Mingqian Feng, Dimiter Dimitrov, Heungnam Kim, Wei Gao
Keywords(s): Antibody-drug Conjugate, chimeric antigen receptor, HCC, hepatocellular carcinoma, IMMUNOTOXINS, Liver cancer
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
Gene Signature for Predicting Solid Tumors Patient Prognosis
Abstract: HCC is the most frequent malignant tumor in the liver and the third leading cause of cancer death worldwide.  A progressive sequence of somatic mutations and epigenetic changes of oncogenes or tumor suppressor genes are believed to cause tumor development. However, high genomic instability in tumors causes the accumulation of genomic aberrations...
Published: 4/8/2024   |   Inventor(s): Xin Wei Wang, Stephanie Roessler
Keywords(s): Biomarker, driver gene, gene signature, HCC, hepatocellular carcinoma, prognostic
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Diagnostics, TherapeuticArea > Oncology
Combination of recombinant IL-7 with Chimeric Antigen Receptor (CAR) T Cells Targeting Glypican-3 (GPC3) for the Treatment of Hepatocellular Carcinoma (HCC)
Abstract: Hepatocellular carcinoma (HCC) is the most common type of liver cancer. standard treatment for HCC is not suitable for a large proportion of liver cancer patients. As a result, alternative treatments are needed. Chimeric antigen receptor (CAR) T cell therapy is a promising alternative approach selectively targets targeting tumors via tumor-specific...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Dan Li, Byung Ha Lee, Sara Ferrando-Martinez
Keywords(s): CAR, Chimeric Antigen Receptor T Cell Therapy, Glypican-3, GPC-3, HCC, hepatocellular carcinoma, HO, Interleukin-7, liver, Recombinant IL-7, Tumor Specific Antigen
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Immunology, Application > Therapeutics
Development and Characterization of the SLC46A3 Knockout Mouse Line
Abstract: Nonalcoholic fatty liver disease is caused by several factors including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), an environmental contaminant. TCDD causes lipid accumulation in humans by inducing the Solute Carrier Family 46 Member 3 (SLC46A3) gene expression. To effectively study TCDD-mediated lipid accumulation, research tools such as...
Published: 4/8/2024   |   Inventor(s): Frank Gonzalez, Sun Hee Yim, Jung-Hwan Kim
Keywords(s): 2, 3, 7, 8-tetracholodibenzo-p-dioxin, Gonzalez, hepatocellular carcinoma, Knockout Mouse, Liver cancer, Major Facilitator Superfamily, MFS, Nonalcoholic fatty liver disease, OBESITY, SLC46A3, Solute Carrier Family, TCDD
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Endocrinology
A Gene-Based Prognostic for Hepatocellular Carcinoma Patient Response to Adjuvant Transcatheter Arterial Chemoembolization
Abstract: Hepatocellular Carcinoma (HCC) is one of the most common cancers worldwide with largely unfavorable outcomes due to a lack of effective treatment options for patients in the later state of disease. The gold standard of care for HCC patients with intermediate to locally advanced tumors is transcatheter arterial chemoembolization (TACE), a procedure...
Published: 4/8/2024   |   Inventor(s): Xin Wei Wang, Valerie Miller
Keywords(s): Gene-Expression Signature, hepatocellular carcinoma, Patient Stratification, prognostic
Category(s): Application > Diagnostics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing
New use of vanoxerine dihydrochloride as an anti-cancer drug for the treatment of liver cancer
 
Published: 1/26/2022   |   Inventor(s): Kwong Sak LEUNG, Xi Nan Shi, Fu Kung Hsiang, Hongjian Li, Man Hon Wong, Chia Mi Marie Lin, Xu Liu, Di Lu
Keywords(s): Anti-cancer Drug, Docking Screening, Fluspirilene, Hepatocellular Carcinoma
Category(s): Biotechnology, Therapeutics